Empiric 131I treatment of high thyroglobulin levels in differentiated thyroid carcinoma after remnant ablation

Basit Öğe Kaydı
dc.authorscopusid54880546000
dc.authorscopusid50461202500
dc.authorscopusid50462801400
dc.authorscopusid36439084200
dc.authorscopusid35949526800
dc.authorscopusid35306945900
dc.contributor.authorKalender, Ebuzer
dc.contributor.authorElboğa, Umut
dc.contributor.authorZeki Çelen, Y.
dc.contributor.authorDeniz Demir, H.
dc.contributor.authorŞahin, Ertan
dc.contributor.authorKaracavuş, Seyhan
dc.date.accessioned2022-05-11T14:40:20Z
dc.date.available2022-05-11T14:40:20Z
dc.date.issued2014
dc.departmentFakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Nükleer Tıp Ana Bilim Dalı
dc.description.abstractAim: The objective of this study is to establish the efficacy of empiric I-131 treatment (EIT) given for patients whose thyroglobulin(Tg) levels remained high after ablative I-131 treatment (AIT). Methods: Fifty-six patients (46 women, 10 men; mean age 47.4±16.8), without distant metastasis, who were treated empirically for high Tg levels after AIT in our clinic, were retrospectively studied. In all patients stimulated Tg levels before AIT (Tg I) and 6 months after AIT (Tg II) were measured. After EIT, post-therapeutic whole-body scintigraphy (PWBS) was performed to all patients. 18F-FDG PET CT was performed to patients who had negative PWBS but continued to have high Tg II levels. Results: PWBS was positive in 28 patients (50%) and negative in 28 patients (50%). Twenty-eight patients did not respond to EIT (50%), and 28 patients (50%) responded to EIT at different rates. Sixteen patients (28.6%) responded to EIT completely, and 12 patients (21.4%) responded to EIT partially. Tg I was 60.7±40 ng/ml and Tg II was 31±20.4 ng/ml in responding patients, whereas Tg I was 87.6±96 ng/ml and Tg II was 114.3±106 ng/ml in unresponding ones. 18F-FDG PET CT was positive in 22 patients and negative in 6. Conclusion: Our findings, suggested that the EIT is not beneficial in patients who have higher Tg II than Tg I and the cure rate is low in increasing Tg levels. The patients who have high Tg II but lower than Tg I can be treated empirically with I-131.
dc.identifier.endpage507
dc.identifier.issn0393-6384
dc.identifier.issue2en_US
dc.identifier.scopus2-s2.0-84898491364
dc.identifier.scopusqualityN/A
dc.identifier.startpage503
dc.identifier.urihttps://hdl.handle.net/20.500.11776/8942
dc.identifier.volume30
dc.indekslendigikaynakScopus
dc.institutionauthorŞahin, Ertan
dc.language.isoen
dc.publisherActa Medica Mediterranea
dc.relation.ispartofActa Medica Mediterranea
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectHigh thyroglobulin levels
dc.subjectfluorodeoxyglucose f 18
dc.subjectiodine 131
dc.subjectthyroglobulin
dc.subjectadult
dc.subjectaged
dc.subjectarticle
dc.subjectcomputer assisted emission tomography
dc.subjectcontrolled study
dc.subjectdifferentiated thyroid cancer
dc.subjectdrug efficacy
dc.subjectfemale
dc.subjecthuman
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectmiddle aged
dc.subjectradioisotope therapy
dc.subjectretrospective study
dc.subjectthyroglobulin blood level
dc.subjecttreatment outcome
dc.subjecttreatment response
dc.subjectvery elderly
dc.subjectwhole body scintiscanning
dc.titleEmpiric 131I treatment of high thyroglobulin levels in differentiated thyroid carcinoma after remnant ablation
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
8942.pdf
Boyut:
114.25 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
Tıp Fakültesi Koleksiyonu